Skip to main content

Table 3 Results of univariate regression analyses

From: The impact of additive or substitutive clinical study design on the negotiated reimbursement for oncology pharmaceuticals after early benefit assessment in Germany

Intercept/Variable

Coefficient

Standard error

t-statistic

p-value

Additive premiums

EU prices (€)

  Intercept

47,112.25243

5916.14299

7.96333904

0.00000682

  X Variable

1.285149844

0.568349354

2.26119698

0.044997465*

Comparable pharmaceuticals (€)

  Intercept

48,424.19167

10,940.20482

4.426260061

0.001017904

  X Variable

0.101908659

0.14325046

0.711401968

0.491646086

Extent of added benefit (minor, considerable)

  Intercept

35,653.9575

18,946.75333

1.881797735

0.086573666

  X Variable

12,040.5225

11,230.66868

1.072110917

0.306628308

AnTC of ACT (€)

  Intercept

59,170.60488

7400.235335

7.995773405

0.00000657

  X Variable

−0.155870503

0.186811151

−0.834374724

0.421820411

Target population size (N)

  Intercept

70,019.62133

7424.38089

9.43103841

0.00000132

  X Variable

−2.195455811

0.862865137

−2.5443789

0.02726661*

Study design (substitutive, additive)

  Intercept

52,933.98625

7243.390467

7.307901803

0.00001527

  X Variable

5642.11975

11,679.61618

0.483074072

0.63851445

Study design (substitutive, additive curative ACT, additive BSC)

  Intercept

36,397.2593

18,310.2111

1.98781211

0.07229695

  X Variable

8106.2683

7572.83041

1.07044102

0.3073464

Multiplicative premiums

EU prices (€)

  Intercept

314.560854

236.23716

1.33154688

0.20994402

  X Variable

0.00380357

0.02269472

0.16759693

0.86994187

Comparable pharmaceuticals (€)

  Intercept

987.783989

290.778295

3.39703481

0.00596027

  X Variable

−0.0099099

0.00380744

−2.6027873

0.02457156*

Extent of added benefit (minor, considerable)

  Intercept

473.047535

656.418807

0.72064897

0.48615854

  X Variable

−83.468655

389.091577

−0.2145219

0.83406515

AnTC of ACT (€)

  Intercept

594.818068

223.036155

2.66691321

0.02191448

  X Variable

− 0.0098356

0.00563031

−1.7468965

0.10847841

Target population size (N)

  Intercept

380.835803

308.693069

1.23370377

0.243024

  X Variable

−0.0062737

0.03587646

− 0.1748683

0.86436022

Study design (substitutive, additive)

  Intercept

545.684925

219.766396

2.48302259

0.03041002

  X Variable

− 539.42557

354.362665

−1.5222415

0.15616375

Study design (substitutive, additive curative ACT, additive BSC)

  Intercept

− 685.50644

547.170559

−1.2528204

0.23624936

  X Variable

443.611998

226.301588

1.96026904

0.07577965

  1. *p < 0.05 for X Variable